Jude Concepcion, the senior legal director at Eisai Inc., took a pugnacious stance when battling pharmaceutical fraud charges; he helped his company settle an off-label marketing case for $11 million without a requirement to overhaul company compliance. The case about improper marketing of the company’s anti-epileptic drug Zonegran settled in December 2010 with the drug’s original owner, Elan Corp., footing the bulk of the $214.5 million bill.
Concepcion, 38, knew that Japanese parent company Eisai Co. Ltd. was inheriting a troubled drug marketing strategy when it bought the drug from Elan in March 2004. But Eisai wanted to make inroads into the U.S. anti-epileptic market, so Concepcion led a quick revamp of the drug’s new promotional materials, along with a retraining of the sales force. It wasn’t enough to avoid a January 2006 subpoena, but avoiding a corporate-integrity agreement was a coup. Eisai insisted it would litigate instead of signing such an agreement, Concepcion said. “We were very aggressive back towards the government.”
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]